| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Rosuvastatin D3 Sodium is deuterium labeled Rosuvastatin (also known as S-4522 and ZD 4522, trade name: Crestor) which is a member of the statin class of drugs and a competitive inhibitor of HMG-CoA reductase with IC50 of 11 nM in a cell-free assay. Rosuvastatin belongs to the statin class that is used for the treatment of high cholesterol and related conditions such as dyslipidemia, and to prevent cardiovascular disease. Its approximate elimination half life is 19 h and its time to peak plasma concentration is reached in 3–5 h following oral administration. In 2013 Crestor was the fourth-highest selling drug in the United States, accounting for approx. $5.2 billion in sales.
| ln Vitro |
|
||
|---|---|---|---|
| ln Vivo |
|
||
| Animal Protocol |
|
||
| References |
Clin Pharmacol Ther.2004 May;75(5):455-63;Bioorg Med Chem.1997 Feb;5(2):437-44.
|
| Molecular Formula |
C22H24D3FN3NAO6S
|
|---|---|
| Molecular Weight |
506.538
|
| Exact Mass |
506.169
|
| CAS # |
1279031-70-7
|
| Related CAS # |
Rosuvastatin Calcium;147098-20-2;Rosuvastatin Sodium;147098-18-8;Rosuvastatin;287714-41-4;Rosuvastatin-d3;1133429-16-9;Rosuvastatin-d6 sodium;2070009-41-3;Rosuvastatin-d6 calcium
|
| PubChem CID |
45359102
|
| Appearance |
Off-white to light yellow solid powder
|
| Melting Point |
>76°C (分解)
|
| LogP |
2.147
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
34
|
| Complexity |
773
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
[2H]C([2H])([2H])N(C1=NC(=C(C(=N1)C(C)C)/C=C/[C@H](C[C@H](CC(=O)[O-])O)O)C2=CC=C(C=C2)F)S(=O)(=O)C.[Na+]
|
| InChi Key |
RGEBGDYYHAFODH-SYRJKFITSA-M
|
| InChi Code |
InChI=1S/C22H28FN3O6S.Na/c1-13(2)20-18(10-9-16(27)11-17(28)12-19(29)30)21(14-5-7-15(23)8-6-14)25-22(24-20)26(3)33(4,31)32;/h5-10,13,16-17,27-28H,11-12H2,1-4H3,(H,29,30);/q;+1/p-1/b10-9+;/t16-,17-;/m1./s1/i3D3;
|
| Chemical Name |
sodium;(E,3R,5S)-7-[4-(4-fluorophenyl)-2-[methylsulfonyl(trideuteriomethyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoate
|
| Synonyms |
Rosuvastatin: (ZD 4522; ZD-4522; ZD4522; S-4522; S 4522; S4522; Brand name: Crestor).
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9742 mL | 9.8709 mL | 19.7418 mL | |
| 5 mM | 0.3948 mL | 1.9742 mL | 3.9484 mL | |
| 10 mM | 0.1974 mL | 0.9871 mL | 1.9742 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Effect of rosuvastatin on thrombin-stimulated leukocyte rolling (upper panel) and leukocyte adherence (lower panel) in rat mesenteric venules.Br J Pharmacol.2001 Jun;133(3):406-12. |
|---|
Mevalonic acid blocks the inhibitory effect of rosuvastatin on thrombin-stimulated leukocyte rolling (upper panel) and leukocyte adherence (lower panel).Br J Pharmacol.2001 Jun;133(3):406-12. |
Leukocyte rolling (upper panel) and leukocyte adherence (lower panel) in peri-intestinal venules of wild-type mice, eNOS−/−mice, and eNOS−/−mice given 1.25 mg kg−1rosuvastatin.Br J Pharmacol.2001 Jun;133(3):406-12. |
Immunohistochemical analysis of P-selectin expression on rat ileal venules, expressed as percentage of venules staining positive for P-selectin.Br J Pharmacol.2001 Jun;133(3):406-12. |
|---|
Effect of rosuvastatin on NO release in rat aortic segments. Basal release of nitric oxide is expressed as nanomoles per mg tissue.Br J Pharmacol.2001 Jun;133(3):406-12. |
Effect of rosuvastatin on thrombin-stimulated leukocyte extravasation. Rat mesenteries were superfused with either K-H buffer alone or with 0.5 u ml−1thrombin. Rosuvastatin (1.25 mg kg−1) was administered intraperitoneally 18 h prior to the study.Br J Pharmacol.2001 Jun;133(3):406-12. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
